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sions were significantly lower for arformoterol patients than Neb-SABA patients
(8.7% vs. 12.1%, p0.0169). Adjusted odds of readmission were estimated to be 44%
less for arformoterol patients (OR 0.56, 95% CI 0.41-0.78). CONCLUSIONS: All-cause
30-day readmissions were significantly fewer for arformoterol patients than neb-
SABA patients, both before and after adjusting for patient and hospital factors such
as ICU care.
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IS IT APPROPRIATE TO MEASURE ASTHMA CONTROLLER ADHERENCE USING
PHARMACY CLAIMS DATA?
Visaria J, Frazee SG, Henderson RR
Express Scripts, Inc., St. Louis, MO, USA
While possession-based adherence measures are typically used to compare med-
ication adherence using pharmacy claims, thesemeasures are difficult to verify for
inhaled asthma medications because the claim-reported days’ supply may not
reflect the actual duration of use. OBJECTIVES: To compare medication adherence
to all asthma controllers to that in subsets of patients using Flucitasone/Salmeterol
disk with inhalation device (combination inhaler, CI) or leukotriene inhibitors (LT)
which are more likely to accurately reflect days’ supply in the claim, across phar-
macy dispensing channels. METHODS: Commercially insured US patients aged
12-63 and medically diagnosed for asthma were followed for one year after initia-
tion of an asthma controller using a retrospective, claims-based design. Adherence
was defined using Medication Possession Ratio (MPR). CI and LT subsets included
all patients using one of these as the indexmedications. Themultivariate-adjusted
relationship between adherence and channel was evaluated using a generalized
linear model. RESULTS: A total of 6014 patients were included in the overall study
cohort, with 2222 in theCI subgroup and 1884 in the LT subgroup. The adjustedMPR
for asthma controllers in the retail pharmacy cohort was 39.70% (95% CI 37.08-
42.52%) compared to 62.43 (95% CI 58.19-66.97%) in the mail-order cohort. In com-
parison, the adjusted MPR for retail andmail-order pharmacy cohorts were 38.33%
(95% CI 34.58 - 42.49%) and 57.85 (95% CI 52.13-64.20%) in the CI subgroup and
49.01% (95% CI 43.83-54.79%) and 69.25 (95% CI 52.13-77.56%) in the LT subgroup,
respectively. CONCLUSIONS: In a large, nationally representative cohort, adher-
ence to asthma controllers and differences in adherence across dispensing chan-
nels were similar inmagnitude to those in two subgroups withmore accurate days
supply information. It may be reasonable to use possession-based asthma adher-
ence measures derived from pharmacy claims, despite potential errors in captur-
ing days’ supply.
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COMPARISON OF RISK ADJUSTMENT MODELS IN PREDICTING DISEASE
SPECIFIC AND TOTAL HEALTH CARE EXPENDITURE FOR COPD
Patel JG, Johnson ML, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: To compare and determine the best risk adjustment model for pre-
dicting disease specific and total health care expenditure associated with Chronic
Obstructive Pulmonary Disease (COPD). METHODS: Data from 2005-2008 Medical
Expenditure Panel Survey, involving adults 18 years with COPD diagnosis were
used to evaluate risk adjustment measures. The outcomes of COPD specific health
care expenditure, total inpatient expenditure, total outpatient expenditure and
total health care expenditure weremodeled using linear regression. Baseline char-
acteristics included age, gender and race. The six different risk adjustment mea-
sures compared were total number of medications, total number of respiratory
medications, D’Hoore-Charlson, Deyo-Charlson, modified Elixhauser and General
Health Status (GHS). Different combinations of thesemeasures were used to derive
the best risk-adjustment model having the highest Adjusted-R2. Validation of the
risk adjustment measures was performed on 2009 MEPS data. RESULTS: Of the six
risk adjustment measures, the total number of respiratory medications performed
best for predicting COPD specific expenditure (Adj. R2: 24.62%). The total number of
medications best predicted inpatient, outpatient and total health care expendi-
tures (Adj. R2: 17.71%, 6.44% and 32.71% respectively). No combination of risk ad-
justment models led any improvement in predicting COPD specific health care
expenditures. The combination of count of all medications with modified Elix-
hauser index performed best in predicting inpatient, outpatient and total health
care expenditure (Adj.R2: 18.44, 7.91 and 34.87 respectively). CONCLUSIONS:Num-
ber of respiratory medications may be an indicator of severity of the disease,
thereby best predicting the disease specific health care expenditure, where as sim-
ple construct of count of all medications used is the best predictor of total health
care expenditure. Medication-based measures can be effective and easy to use in
risk-adjusting health care expenditures.
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1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada
OBJECTIVES:Medical interventions are often administered as treatment combina-
tions (e.g., drug A  drug B). Models for effects of treatment combinations in mul-
tiple treatment comparison meta-analysis (MTCs) have previously been proposed.
The objective of this studywas to evaluate the comparative statistical performance
of the conventional MTC model and an ‘additive effects’ MTC model, in scenarios
where ‘additivity’ holds true (i.e., where the effect of effect of treatment A and B
combined is equal to the sumof the individual effects of treatmentA and treatment
B) and in scenarios where ‘additivity’ is mildly or strongly violated.METHODS:We
simulated MTC scenarios where additivity held true or was violated. We applied
conventional and additive effects Bayesian MTCmodels to the simulated data. We
measured the proportion of over- and underestimated treatment effects, the cov-
erage of the 95% credible intervals, and the statistical power. RESULTS: Under true
additivity, the additive effects model is superior to the conventional model. Under
mildly violated additivity, the additive model is less accurate (more over- and
underestimates), but more precise (comparable coverage and greater power). Un-
der strongly violated additivity, the additive model performs worse in terms of
accuracy and coverage. CONCLUSIONS: The additivemodel may readily be used in
practice when approximate additivity can be assumed.
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Flood E1, Devlen J1, Zazzali J2
1Oxford Outcomes Ltd., an ICON PLC Company, Bethesda, MD, USA, 2Genentech, Inc., South San
Francisco, CA, USA
OBJECTIVES: The Urticaria Patient Daily Diary (UPDD), originally developed in pa-
per format, has beenmigrated to an electronic version. This study was designed to
assess the test-retest reliability of the electronic version (ePRO) of the UPDD.
METHODS: The UPDD includes a morning component, assessing CIU symptoms
and impact on sleep, and an evening component, assessing symptoms, impact on
daily activities, rescue medication use, and contacting a health care provider.
Adults and adolescents with moderate to severe chronic idiopathic urticaria (CIU)
completed the morning and evening ePRO UPDD once, engaged in an hour-long
filler task (Sudoku puzzles), and then completed the UPDD again. Test-retest reli-
ability between the two UPDD completions was assessed by item using a weighted
Kappa, a simple Kappa for a dichotomous item (angioedema), and McNemar’s test
for one item (calling a doctor/nurse). Intraclass correlation coefficients (ICCs) as-
sessed the reliability of the Urticaria Activity Score (UAS), which is the sum of the
‘itch severity’ and ‘number of hives’ item scores. RESULTS: Forty-five patients aged
13 to 74 years (mean 43.6 years) with stable symptoms at time of diary completion
participated. Kappa values ranged from 0.83 to 1.00 for the ePRO UPDD items. The
McNemar’s test yielded a non-significant p-value (p 0.317). For the UAS, ICC was
0.83 for the morning ePRO UPDD and .96 for the evening ePRO UPDD; each of the
Wilcoxon p-values was greater than 0.05. CONCLUSIONS: All Kappas were above
the 0.74 threshold (Coons et al, 2009), indicating excellent test-retest reliability. No
significant differenceswere found between test and retest scores on the UAS or the
‘contacting health care provider’ item. In summary, the ePRO UPDD showed excel-
lent test-retest reliability in a sample of CIU patients whose symptoms were stable
at time of UPDD completion.
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OBJECTIVES: The original interviewer-administered versions of the Baseline/Tran-
sition Dyspnea Indexes (BDI/TDI) were modified by the originator to create self-
administered and computerized (SAC) versions. The rationale for the development
of the SAC versions was to offer a standardized method for patients to report the
impact of activities of daily living on the severity of their breathlessness. The
objective of this study is to present the acceptability of the SAC versions of the
BDI/TDI to patients with COPD from seven countries including eight different lan-
guages [Dutch (The Netherlands), English (Canada, UK), Flemish (Belgium), French
(Belgium, Canada), German (Germany), and Spanish (Spain)]. METHODS: A stan-
dardized methodology was followed to translate the SAC BDI/TDI (e.g., forward/
backward step, review by author). The test on 5 COPD patients in each country was
conducted in form of in-depth interviews to evaluate 1) comprehension, and 2)
acceptability using laptop computers. RESULTS: Overall, most patients liked the
SAC versions, and about half preferred it to a interviewer-administered question-
naire. Only four of 35 patients had problems using the mouse to click on the right
answer for the BDI (e.g., difficulties of coordination, or in using the left button). The
items were understood with no difficulties; themain challenging issue was ease in
understanding the equivalents of “Baseline” and “Transition”. At first, 42% of the
patients, especially in Germany (4/5 patients), Spain and UK (3/5 patients), had
difficulties with the instructions to select answers on the TDI using the up-and-
down elevator buttons. These difficulties did not persist after the practice question
designed to help the patients to become familiar with clicking an “X” (BDI), and using
the up-and-down arrows (TDI). CONCLUSIONS: The SAC versions of the BDI/TDI
were well accepted by patients from seven different countries. Special attention
and supervision should be given to patients not familiar with computer use.
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A NEW CONCEPT OF PATIENT REPORTED OUTCOME ON QUALITY INDICATORS
FOR PHARMACEUTICAL CARE
Huttin C
ENDEPUSresearch and ENDEPResearch Group, Cambridge, MA, USA
OBJECTIVES: A new concept of Patient-Reported Outcome (PRO) on quality indica-
tors for pharmaceutical services is presented. It aims to supplement postmarketing
surveillance tools. It is based on research findings fromapatient survey instrument
designed at Harvard and applied to a Primary Care Group in Warwickshire, as a
quality improvement tool (Value inHealth, vol 5, issue 3, 2002). AHRQ considers the
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